Advertisement

Hematologic Malignancies
Health-Care Policy

The Inflation Reduction Act and Ibrutinib

In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list price. This new price will go into effect in January 2026. Negotiations began following passage...

Lung Cancer

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...

Lung Cancer

Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update

ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...

Lung Cancer

Patients With Interstitial Lung Disease Face Elevated Lung Cancer Risk, Study Finds

A large prospective cohort study conducted by Ye and Kang et al and published in JAMA Network Open found that, after adjusting for familial and other cancer-related factors, interstitial lung disease (ILD) was associated with an increased risk of developing most histologic subtypes of lung cancer.

...

Breast Cancer
Survivorship

Intense Resistance Training for Breast Cancer Survivors With Lymphedema Risk

Resistance training can provide many benefits, including increased muscle mass; decreased adipose tissue; and improved metabolism, bone density, strength, and mobility. However, data are limited on the association between resistance training and the development or exacerbation of lymphedema, a...

CNS Cancers

Patritumab Deruxtecan Shows Efficacy in Leptomeningeal Metastases From Solid Tumors

The HER3-directed antibody-drug conjugate patritumab deruxtecan demonstrated clinical efficacy in treating patients with leptomeningeal metastatic disease of solid tumors, according to findings from a cohort of the phase II TUXEDO-3 trial. Researchers were also encouraged by the intracranial...

Issues in Oncology

Realizing the Full Potential of Patient Engagement in Clinical Research

Nothing about us without us is a centuries-old value that is a cornerstone of meaningful patient engagement in clinical research. Such engagement has not been automatic and is still largely absent in geriatric oncology research, where older patients traditionally have been excluded from clinical...

Lymphoma

Fertility Outcomes in Patients of Childbearing Potential Receiving First-Line Therapy for Advanced Lymphoma

In an analysis reported in The Lancet Oncology, Ferdinandus et al found that among patients with newly diagnosed advanced-stage classical Hodgkin lymphoma who were of childbearing potential (POCBP) in the phase III HD21 trial, those receiving BrECADD (brentuximab vedotin, etoposide,...

ASTRO Announces New President-Elect, Officers

The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors:

  • Catheryn M. Yashar, MD, FASTRO, President-Elect
  • Jonathan Strauss, MD, MBA, Secretary/Treasurer-Elect
  • Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair
  • ...

Leukemia
Lymphoma

Noncovalent BTK Inhibitor in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In a phase III trial (BRUIN CLL-321) reported in the Journal of Clinical Oncology, Sharman et al compared treatment outcomes with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib vs investigator choice of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR) in patients ...

Leukemia

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...

Breast Cancer

HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer

In an individual patient-level meta-analysis reported in The Lancet Oncology, Villacampa et al found that the HER2DX assay risk score was prognostic for event-free survival outcomes in patients with early-stage, HER2-positive breast cancer.

Study Details

Systematic review of the literature...

Colorectal Cancer

Association of Type 2 Diabetes With Colorectal Cancer Risk and Survival by Tumor Immunity Status

In a German population–based, matched case-control study reported in the Journal of Clinical Oncology, Wankhede et al found that type 2 diabetes (T2D) may be associated with colorectal cancer (CRC) risk and survival according to tumor immunity status.

Study Details

The study included 1,889 CRC...

Lung Cancer

NSCLC Trial Shows Radiation May Overcome Primary Resistance to Pembrolizumab

The addition of radiation may be able to surmount resistance to immunotherapy for some more immunologically “cold” tumors, as suggested by the findings of a study focused on the immunomodulatory effects of radiation in non–small cell lung cancers (NSCLCs). The research was recently published in

American Cancer Society Names New CEO

The American Cancer Society (ACS) and its advocacy affiliate the American Cancer Society Cancer Action Network (ACS CAN) have announced Shane Jacobson as their Chief Executive Officer, effective August 12, 2025. He steps into the role following Wayne A.I. Frederick, MD, MBA, FACS, who has served as ...

Lung Cancer

Final Overall Survival Analysis of FLAURA2: Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC

Positive results from the final overall survival analysis of the phase III FLAURA2 trial showed that osimertinib (a third-generation, irreversible EGFR tyrosine kinase inhibitor) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically...

Colorectal Cancer

Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal

In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Study Details

In the...

Legislation
Health-Care Policy

CBO Report Finds Federal Cuts to NIH Would Threaten New Drug Development and Innovation

A new report from the nonpartisan Congressional Budget Office (CBO) has found that proposed cuts at the National Institutes of Health (NIH) could lower the number of new drugs that come to market in the next 3 decades. The report comes as Congress considers President Trump’s proposed budget for...

Genomics/Genetics

Biomarker Testing in Advanced Cancer: Suboptimal Rates Despite Guideline Recommendations and Growing Insurance Coverage

A retrospective cohort study reported in JAMA Network Open revealed that biomarker testing rates among patients with advanced cancer have increased over time but remain suboptimal, despite established guideline recommendations and growing insurance coverage for testing. DaCosta Byfield et al noted...

Breast Cancer

Short-Term Hormonal Treatment Offers Early Insight Into Tumor Behavior and Resistance for ER+/HER2+ Breast Cancer

How ER-positive, HER2-positive breast cancer tumors respond to a short course of hormonal treatment may help to determine whether more aggressive treatment options are necessary for each patient or not, according to translational findings published in eBioMedicine. Tumor subtype changes after 2...

Issues in Oncology

Evaluation of Racial Classification Standards in U.S. Cancer Surveillance Systems

Despite multiple federal updates to race data collection standards, researchers have found persistent discrepancies in how cancer incidence and mortality rates are recorded for racial minorities—particularly multiracial individuals. A recent study in Cancer highlights how evolving definitions of...

Breast Cancer

Breastfeeding Patterns After Treatment of Early Hormone Receptor–Positive Breast Cancer

In a prospective study (POSITIVE) reported in the Journal of Clinical Oncology, Peccatori et al investigated breastfeeding patterns among women who had a live birth after treatment of hormone receptor–positive breast cancer.

Study Details

Between December 2014 and December 2019, 518 women who...

Survivorship

Study Finds No Difference in Dietary Habits Between Cancer Survivors and General Population

Researchers have discovered that most cancer survivors do not make significant improvements to their diet or eating habits after their cancer diagnosis, according to findings published in Public Health Nutrition. Despite their cancer diagnosis, there was no significant difference in diet-related...

Gynecologic Cancers

Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer

In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer.

Study Details

In the multicenter,...

Multiple Myeloma

DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma

In an analysis from the phase III DREAMM-7 trial reported in The Lancet Oncology, Hungria et al compared survival outcomes with belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma...

Skin Cancer

Extended Follow-up for Neoadjuvant and Adjuvant Relatlimab Plus Nivolumab in Resectable Melanoma

In an extended follow-up of a phase II trial reported in the Journal of Clinical Oncology, Burton et al examined outcomes with neoadjuvant and adjuvant relatlimab-rmbw plus nivolumab in patients with resectable melanoma. Relatlimab targets LAG3, while nivolumab targets PD-1.

Study Details

In the...

Issues in Oncology

Alcohol-Associated Cancer Death Rates Are Climbing

Alcohol-associated cancer deaths have doubled in the United States, disproportionately affecting men and those aged 55 or older, according to the results of an observational study presented at the 2025 ASCO Annual Meeting.1 Over the study period of 30 years, proportional mortality rates increased...

COVID-19

Real-World Data Show COVID-19 Boosters Offer Protection for Patients With Cancer

COVID-19 vaccine boosters for adult patients with cancer helped to keep these patients from being hospitalized or admitted to intensive care units due to severe COVID-19 infections, according to the results of a retrospective cohort study published in JAMA Oncology

“Cancer patients are a...

Breast Cancer

Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes?

Aprepitant, a commonly used antiemetic, led to improvements in patient outcomes when given during chemotherapy treatment for patients with non-luminal early breast cancer. Patients showed better prognoses and survival advantages, particularly among those with triple-negative breast cancer. Study...

Bladder Cancer

Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates

As reported in JAMA Network Open by Mamtani et al, a retrospective cohort study of patients with metastatic urothelial cancer showed population-level increases in survival after the introduction of novel cancer therapeutics—immune checkpoint inhibitors (ie, pembrolizumab and atezolizumab) and...

Colorectal Cancer

Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer

In an analysis from the French SAMCO-PRODIGE 54 trial reported in JAMA Oncology, Taïeb et al examined survival outcomes associated with a change in ctDNA from baseline to 1 month after start of treatment in patients receiving ICI treatment with avelumab for deficient mismatch repair/microsatellite...

Issues in Oncology

Classifying Pancreatic Cysts Using AI Models

In a proof-of-concept study published in the Journal of the American College of Surgeons, researchers investigated whether artificial intelligence (AI) models such as ChatGPT-4 can be used to accurately extract and classify diagnostic data from radiologic imaging reports of pancreatic cysts. The...

Lymphoma
Geriatric Oncology

Outcomes Support CAR T-Cell Therapy Use in Elderly Patients With B-Cell Lymphomas

Patients in their 80s or older with B-cell lymphomas are able to receive chimeric antigen receptor (CAR) T-cell therapy safely, results of a multicenter retrospective study published in Bone Marrow Transplantation showed. These patients are usually not eligible for clinical trials of CAR T-cell...

Thyroid Cancer

Thyroidectomy Without Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer

In a UK phase III trial (IoN) reported in The Lancet, Mallick et al compared survival outcomes among patients with low-risk differentiated thyroid cancer who underwent thyroidectomy with no postoperative radioiodine ablation vs thyroidectomy plus ablation.

Study Details

In the multicenter...

Gastrointestinal Cancer

Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945

A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...

Cardio-oncology

Studies Explore Cardiac Risks and Clinical Characteristics Associated With Immune Checkpoint Inhibitor–Related Myocarditis

Immune checkpoint inhibitors (ICIs) have significantly impacted treatment options for a wide range of cancers given their efficacy, especially among cancer types that are considered immunologically “hot.” With this broad benefit across many tumor types, researchers continue to look for ways to...

Issues in Oncology

Study Links Childhood Proximity to Radiation-Contaminated Coldwater Creek With Elevated Cancer Odds

Living near Coldwater Creek in St. Louis, Missouri, during childhood was found to be associated with an increased risk of overall cancer, according to the findings of a study published in JAMA Network Open

“Our research indicates that the communities around North St. Louis appear to have had...

Gynecologic Cancers

Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer

The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall...

Lymphoma

New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma

The first individualized risk prediction model for adults with early-stage classical Hodgkin lymphoma (cHL) has been developed and validated. According to a report published in NEJM Evidence, the Early-Stage cHL International Prognostic Index (E-HIPI) model estimates 2-year progression-free...

Issues in Oncology

Survey Highlights Top Anxiety Points for Caregivers After a Cancer Diagnosis

New survey findings highlight that the anxiety caused by a cancer diagnosis extends far beyond just the patient diagnosed. The emotional impact is shared by caregivers and loved ones, with stress, grief, and worry over treatments, pain, and life expectancy weighing heavily on these individuals,...

Hepatobiliary Cancer

Risk of Liver Cancer With Oral Contraceptive Use

In a UK population-based study reported in The Lancet Oncology, Watling et al examined the relationship between ever use vs never use of oral contraceptives and the risk of liver cancer. Some findings suggested the possibility of slightly increased risk with longer-term use. 

As noted by the...

Lymphoma

Lisocabtagene Maraleucel as Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up

As reported in the Journal of Clinical Oncology by Kamdar et al, the 3-year follow-up of the phase III TRANSFORM trial showed that lisocabtagene maraleucel (liso-cel) maintained superior efficacy vs standard of care (SOC) in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL). ...

Issues in Oncology

People With Acromegaly Face Elevated Cancer Risk, Study Finds

A new study presented at the 2025 Annual Meeting of the Endocrine Society (ENDO 2025) found that individuals with acromegaly—an endocrine disorder caused by excessive growth hormone secretion—are at a significantly heightened risk of developing various types of cancer, often at younger ages...

Lung Cancer

Resectable NSCLC: Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy

In an analysis from the phase III CheckMate 816 trial reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Forde et al examined overall survival outcomes with the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with stage IB to IIIA...

Thyroid Cancer
Neuroendocrine Tumors

Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers

Researchers have developed a novel AI-powered online platform for diagnosing endocrine cancers with speed and accuracy. The AI models achieved diagnostic accuracy of 99% or more in recognizing multiple endocrine tumors. Reports of the development and validation of the models were presented at ENDO...

Lung Cancer

New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies

Linear endobronchial guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (CT-guided) or a bronchoscopic approach. There have been few...

Leukemia

MRD-Guided Therapy With Ibrutinib/Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia

In an update from the UK phase III FLAIR trial reported in The New England Journal of Medicine, Munir et al compared the survival benefit of measurable residual disease (MRD)–guided therapy with ibrutinib/venetoclax vs ibrutinib alone in chronic lymphocytic leukemia.

An interim analysis showed...

Prostate Cancer

Metformin in Metastatic Prostate Cancer

In a phase III trial (part of the STAMPEDE platform) reported in The Lancet Oncology, Gillessen et al investigated the survival outcomes of adding metformin to standard of care (SOC) in nondiabetic patients with metastatic hormone-sensitive prostate cancer starting androgen-deprivation therapy...

Multiple Myeloma

Teclistamab for High-Risk, Heavily Pretreated Multiple Myeloma: Real-World Data

Teclistamab-cqyv is the first bispecific T-cell engager antibody that targets both B-cell maturation antigen (BCMA) proteins on myeloma cells and CD3 proteins on T cells. It was approved by the U.S. Food and Drug Administration in 2022 for treatment of patients with relapsed or refractory multiple...

Leukemia

Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations

A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia (AML) and an NPM1 mutation or KMT2A rearrangement. The regimen was also shown to be safe in updated results from ...

Leukemia

Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models

A combination of menin inhibition and KAT6A/7 inhibition significantly improved survival for NUP98-rearranged pediatric acute myeloid leukemia (AML) in AML model systems, even in menin inhibitor–resistant cells, according to findings published in Cancer Discovery.

The MYST gene family histone...

Leukemia

Can Planned C-Sections Increase the Risk of Childhood ALL?

Children born by planned cesarean section (C-section) may have an increased risk of developing acute lymphoblastic leukemia (ALL) later in life, according to a recent study published by Kampitsi et al in the International Journal of Cancer. Alhough the researchers did find an association, they...

Lung Cancer

Phase II Trial Supports SRT as Alternative to WBRT in SCLC

Patients with small cell lung cancer (SCLC) that has metastasized to the brain were safely and successfully treated with targeted stereotactic radiation (SRT) rather than whole-brain radiation therapy (WBRT) in a phase II trial, demonstrating the practicality of a less-invasive approach for...

Lung Cancer

Outcomes With Perioperative Immunotherapy in Resectable NSCLC

In a retrospective cohort study reported in JAMA Network Open, Desai et al examined survival outcomes with the addition of immunotherapy to neoadjuvant or adjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC).

Study Details

The study involved data from the Flatiron...

Issues in Oncology

Sharp Rise in Obesity-Linked Cancer Mortality Highlights Geographic and Demographic Gaps

Obesity-related cancer deaths have tripled in the United States over the past 2 decades, with significant disparities seen by gender, race, age, and geography, according to findings from a national epidemiological analysis presented at ENDO 2025, the annual meeting of The Endocrine Society (

Issues in Oncology
Solid Tumors

Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk

Treating drinking water for multiple contaminants, especially arsenic and chromium-6, could prevent more than 50,000 cancer cases in the United States, according to the results of a study by the Environmental Working Group that was published in Environmental Research

Study findings highlighted...

Prostate Cancer

New Research Offers Reassurance About Localized Prostate Cancer Prognosis

A recent study out of Sweden found that people diagnosed with nonmetastatic low-risk prostate cancer later in life were 90% more likely to survive their cancer for their remaining life expectancy if they were treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Of...

Skin Cancer

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneous squamous cell carcinoma.

Study Details

In the U.S. multicenter trial, 57 evaluable patients...

Hepatobiliary Cancer

Surgery vs Ablation in Small Hepatocellular Carcinoma

In two Japanese studies (SURF-RCT and SURF-Cohort) reported in the Journal of Clinical Oncology, Kawaguchi et al compared the outcomes of surgery vs radiofrequency ablation (RFA) in patients with small hepatocellular carcinoma (HCC).

Study Details

Two multicenter studies were performed, with...

Hepatobiliary Cancer

Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial

In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...

Hematologic Malignancies

The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies

Over the past 20 years, increased understanding of the biological mechanism of disease has led to improved treatment options for all malignancies. Within each disease subtype, we have molecularly characterized tumors and developed specific treatment algorithms to optimize patient outcomes.

Among...

Skin Cancer

Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma

A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...

Gynecologic Cancers

Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

In the phase III ROSELLA trial—reported at the 2025 ASCO Annual Meeting as well as in The Lancet—Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorilant is a first-in-class selective glucocorticoid receptor...

Skin Cancer

RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma

When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...

Issues in Oncology
Symptom Management

Ruxolitinib for Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease

In the 3-year final analysis of the phase III REACH3 trial reported in the Journal of Clinical Oncology, Zeiser et al compared the use of ruxolitinib vs best available therapy (BAT) in terms of failure-free survival and duration of response in patients with steroid-refractory or -dependent chronic...

Gastroesophageal Cancer

Literature Review Highlights Rising Incidence and Disparities in Many Early-Onset GI Cancers

Rates of early-onset gastrointestinal cancers, beyond just colorectal cancer, are rising among people younger than age 50, according to experts from Dana-Farber Cancer Institute. Researchers from Dana-Farber published a literature review in the British Journal of Surgery showing that cases of newly ...

Hematologic Malignancies

A Young Hematologist’s Take on ICML 2025

From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an innovative chemotherapy-free approach to treating lymphoma)—the nostalgia at the International...

Head and Neck Cancer

AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging

An update of staging guidelines from the American Joint Committee on Cancer (AJCC) for human papillomavirus (HPV)-positive throat cancer—now more common in the United States than cervical cancer, according to the American Cancer Society—aims to make treatment of early-stage disease more consistent...

Gastroesophageal Cancer

Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma

In a phase II trial reported in The Lancet Oncology, Elimova et al evaluated the efficacy and safety of the bispecific monoclonal antibody zanidatamab plus chemotherapy in the first-line treatment of patients with advanced HER2-positive gastroesophageal adenocarcinoma.

Study Details

In the...

Gynecologic Cancers
Geriatric Oncology

Women Over the Age of 65 Still at Heightened Risk of HPV-Related Cervical Cancer

Women aged 65 years and older are still at a heightened risk of cervical cancer caused by human papillomavirus (HPV), suggest the findings of a large observational Chinese study published by Ye et al in Gynecology and Obstetrics Clinical Medicine.

Most guidelines currently recommend discontinuing...

Lung Cancer
Immunotherapy

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

Corticosteroids, which are commonly prescribed to alleviate cancer-related symptoms in patients with non–small cell lung cancer (NSCLC) treated with immunotherapy, may be the reason certain immunotherapies fail in treating the disease, according to new research published by Polyakov et al in Cancer ...

Survivorship

Subsequent Neoplasm Risk Among Childhood Cancer Survivors: Effect of BMI and Physical Activity

In a study reported in JAMA Oncology, Joffe et al examined the association of high body mass index (BMI) and low physical activity with increased risk of subsequent neoplasms among childhood cancer survivors.

Study Details

The study involved data on 5-year survivors of childhood cancers...

Lymphoma

Nivolumab or Brentuximab Vedotin With AVD in Older Patients With Advanced Classical Hodgkin Lymphoma

In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD (doxorubicin, vinblastine, dacarbazine; N-AVD) vs brentuximab vedotin plus AVD (BV-AVD) in patients with advanced-stage...

COVID-19
Survivorship

Adult Survivors of Childhood Cancer May Be at Increased Risk of Severe COVID-19 Infection

People who have survived cancer as children may be at a higher risk of developing severe COVID-19 infection—even decades after their cancer diagnosis, according to results published by Louro et al in The Lancet Regional Health – Europe.

Thanks to medical advances, more and more children are...

Breast Cancer

BMI and Cardiovascular Disease Associated With Increased Breast Cancer Risk

Weight-associated risk for developing breast cancer after menopause may be higher among women with cardiovascular disease compared with those without cardiovascular disease and women with or without type 2 diabetes, according to the results of two prospective European cohort studies, which were...

Leukemia

Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies

Investigators have bioengineered an organotypic immunocompetent chip—a laboratory device that combines the physical structure of human leukemia bone marrow and a functioning immune system—to empower real-time spatiotemporal monitoring of CAR-T cell functionality for leukemias. The preclinical...

Lymphoma

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL

In an Australian phase II trial (COALITION) reported in the Journal of Clinical Oncology, Minson et al investigated the addition of glofitamab to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide,...

Hepatobiliary Cancer

Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC

The U.S. Food and Drug Administration (FDA) has approved SIR-Spheres Y-90 resin microspheres, manufactured by Sirtex, for the treatment of unresectable hepatocellular carcinoma (HCC). With this approval, these microspheres become the only radioembolization therapy approved for the treatment of both ...

Breast Cancer

Survey Finds Confusion Over Mammogram Guidelines

Mammograms can detect breast cancer early before symptoms appear, and regular screening decreases the risk of dying from breast cancer. But a recent survey conducted by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania shows that some Americans appear to be confused about...

Cost of Care

Survival Disparities Rise in Patients With Advanced Cancer Depending on Whether They Have Insurance to Cover Immune Checkpoint Inhibitors

A study led by researchers at the American Cancer Society examining the association between the introduction of immune checkpoint inhibitors (ICIs) and changes in survival disparities by health insurance coverage among patients with newly diagnosed stage IV melanoma, non–small cell lung cancer...

Skin Cancer

Intratumoral BO-112 With Pembrolizumab in Anti–PD-1–Resistant Melanoma

In a Spanish-French phase II trial (SPOTLIGHT-203) reported in the Journal of Clinical Oncology, Márquez-Rodas et al investigated the combination of the intratumoral agent BO-112 and pembrolizumab for activity in patients with advanced anti–PD-1–resistant melanoma. BO-112 is a synthetic,...

Lung Cancer

Air Pollution Linked to Distinct Genomic Signatures in Lung Cancers Among Never-Smokers

A large analysis of the mutational processes of lung cancers in never-smoker patients showed that exposure to fine-particulate air pollution was strongly associated with increased genomic changes, including in cancer-driving and cancer-promoting genetic mutations. Findings from the whole-genome...

Lung Cancer

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib (Zegfrovy), a selective EGFR tyrosine kinase inhibitor, for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an...

Gynecologic Cancers

PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma

 

Patients with ovarian clear cell carcinoma harboring PPP2R1A mutations showed significantly improved survival when treated with immunotherapy compared with those without PPP2R1A mutations, according to study findings published in Nature

Preclinical findings from the study also suggested that...

Kidney Cancer

Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

In a National Cancer Institute phase II trial reported in The New England Journal of Medicine, Srinivasan et al investigated whether the monoclonal antibody bevacizumab in combination with the EGFR inhibitor erlotinib showed activity in patients with advanced hereditary leiomyomatosis and renal...

Colorectal Cancer

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer

In a French phase II trial (LEANOX) reported in the Journal of Clinical Oncology, Assenat et al examined survival outcomes and oxaliplatin-induced peripheral neurotoxicity (OIPN) risk associated with lean body mass (LBM)-based oxaliplatin dosing in the adjuvant treatment of stage III colon cancer.

...

Multiple Myeloma

FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (Lynozyfic), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...

Solid Tumors
Hematologic Malignancies

Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells

Many cytotoxic chemotherapy agents have long-term biological consequences, including premature aging of the cell population structure of healthy blood, the results of a study of the genetic effects of chemotherapy showed. These findings published in Nature Genetics may help to guide future...

Breast Cancer

Can Hormone Therapy Affect Breast Cancer Risk in Younger Women?

Investigators have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use this type of hormone therapy. Additionally, women...

Gynecologic Cancers

Uterine Cancer Incidence and Mortality Rates Projected to Rise Substantially by 2050

Uterine cancer is the fourth most common cancer diagnosed in women in the United States, with about 69,120 new cases and nearly 14,000 deaths from the disease expected this year. Black women experience a twice as high mortality rate compared with women of other races and ethnicities, and that...

Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: Comparison of Second-Line Regimens

As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (ARPI) in patients with castration-resistant prostate cancer with extrapelvic soft-tissue metastases...

Breast Cancer

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

Panoramic photoacoustic computed tomography (PACT) with machine learning assistance could be a safe, noninvasive, and sensitive alternative to mammography, ultrasound, and magnetic resonance imaging (MRI) for breast cancer screening, according to study results that were published in Nature...

Lung Cancer

HER3-DXd in NSCLC Without EGFR-Activating Mutations

As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) in patients with advanced squamous or nonsquamous non–small cell lung cancer (NSCLC) without a...

Solid Tumors

Survey Shows Inaccuracies in U.S. Perceptions of Testicular Cancer

Only about 13% of U.S. adults correctly reported that testicular cancer is most common among men younger than 40, according to the results of a survey.

The survey, commissioned by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research ...

Bladder Cancer

utDNA May Help to Personalize Bladder Cancer Treatment

Results of a multi-institutional study published by St-Laurent et al in Science Direct revealed that testing urine-based tumor DNA (utDNA) may help to predict which patients with bladder cancer are at higher risk for recurrence after not responding to first-line treatment.

The study analyzed utDNA ...

Issues in Oncology
Global Cancer Care

Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests

About one in six tested chemotherapies in sub-Saharan Africa were found to have serious quality defects, according to the results of a study published in The Lancet Global Health.  

Researchers assessed the appearance, packaging, and labeling of each cancer medication and measured the quantity of...

Breast Cancer

Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes

As reported in The Lancet Oncology by Kirby et al, 10-year follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence (IBTR) outcomes compared with whole-breast radiotherapy...

Bladder Cancer
Immunotherapy

Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper-Tract Urothelial Carcinoma

In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper tract urothelial carcinoma.

Study Details

In this multicenter open-label trial, 45...

Colorectal Cancer

Patterns of ICI Use and Survival Outcomes in Metastatic Colorectal Cancer

In a U.S. population–based cohort study reported in JAMA Network Open, Bari et al identified patterns of immune checkpoint inhibitor (ICI) use and survival outcomes among patients with metastatic colorectal cancer seen in routine clinical practice.

The investigators stated: “…ICIs have been...

Colorectal Cancer

Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer

In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality.

Study Details

In the multicenter study, eligible...

Advertisement

Advertisement




Advertisement